🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.380
0.00 (0.00%)
At close: Nov 18, 2026, 4:00 PM EST
1.390
+0.010 (0.72%)
After-hours: Nov 18, 2026, 4:20 PM EST

Inhibikase Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Inhibikase Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.55. The average 1-year stock price forecast is 302.17% higher than the current stock price, while the lowest is $1.50 (+8.70%) and the highest is $8.00 (+479.71%).

Price Target: $5.55 (+302.17%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$1.50$5.55$5.50$8.00
Change+8.70%+302.17%+298.55%+479.71%

Analyst Ratings

The average analyst rating for Inhibikase Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy788887
Buy111111
Hold000011
Sell000000
Strong Sell000000
Total8999109

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aNov 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$8
BuyReiterates$8+479.71%Nov 13, 2026
Maxim Group
Maxim Group
Buy
Maintains
$8
BuyMaintains$8+479.71%Nov 12, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$5
BuyMaintains$5+262.32%Nov 11, 2026
Chardan Capital
Chardan Capital
Hold
Initiates
$1.5
HoldInitiates$1.5+8.70%Oct 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.41
EPS Next Year
-0.40
from -0.41
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.10M123.44K260.50K---
Gross Profit
-8.26M-11.91M-13.36M---
Gross Margin
-266.35%-9,649.66%-5,127.75%--70.00%
Operating Income
-14.77M-18.13M-20.09M-28.59M-45.95M-84.02M
Net Income
-14.79M-18.05M-19.03M-27.52M-48.26M-77.76M
EPS
------0.41
Free Cash Flow
-----27.80M-63.00M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-0.38
Avg-0.41
Low-0.42

EPS Growth

EPS Growth20272028
High-
Avg-
Low-